Arcus Biosciences, Inc. (NYSE: RCUS) is a Healthcare company (Biotechnology) with a market capitalization of $2.4B. The Maz Rating grades it against the other companies in its sector.
Arcus Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.86, Arcus Biosciences, Inc. trades at 24.3x sales and 6.0x book value. Over the last twelve months it generated about $100M of revenue and a net loss of $526M. It runs a gross margin of 95.0%, an operating margin of -475.0% and a net margin of -445.0%. It shows return on equity of -90.0%, return on invested capital of -75.0% and a free cash flow yield of -19.2%. On the balance sheet: a debt-to-equity ratio of 0.32 and a current ratio of 3.34. Over the past 52 weeks the share price ranged from $16.76 to $31.74, with a beta of 0.81.
Arcus Biosciences, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 15 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.